Synthetic factors affecting the stability of methylammonium lead halide perovskite nanocrystals.

Lead halide perovskite nanocrystals (PNCs) have emerged as promising candidates for use in optoelectronic devices. Significant focus has been directed towards optimising synthetic conditions to obtain PNCs with tunable emission properties. However, the reproducible production of stable PNC dispersions is also crucial for fabrication and scale-up of these devices using liquid deposition methods. Here, the stability of methylammonium lead halide (MAPbX3 where X = Br, I) PNCs produced via the ligand-assisted reprecipitation process is explored. We have focussed on understanding how different combinations of specific synthetic factors - dilution, halide source and ratio as well as capping-ligand concentration - affect the stability of the resultant PNC dispersion. Photoluminescence spectroscopy, transmission electron microscopy and dynamic light scattering studies revealed that subtle changes in the reaction conditions lead to significant changes in the particle morphology and associated optical properties, often with catastrophic consequences on stability. This study highlights the importance of designing PNC dispersions in order to make more efficient and reliable optoelectronic devices.This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 818762 - SPECTRACON)

SN2019wxt: An ultrastripped supernova candidate discovered in the electromagnetic follow-up of a gravitational wave trigger

We present optical, radio, and X-ray observations of a rapidly evolving transient SN2019wxt (PS19hgw), discovered during the search for an electromagnetic counterpart to the gravitational-wave (GW) trigger S191213g. Although S191213g was not confirmed as a significant GW event in the off-line analysis of LIGO-Virgo data, SN2019wxt remained an interesting transient due to its peculiar nature. The optical/near-infrared (NIR) light curve of SN2019wxt displayed a double-peaked structure evolving rapidly in a manner analogous to currently known ultrastripped supernovae (USSNe) candidates. This double-peaked structure suggests the presence of an extended envelope around the progenitor, best modeled with two components: (i) early-time shock-cooling emission and (ii) late-time radioactive 56Ni decay. We constrain the ejecta mass of SN2019wxt at Mej ≈ 0.20M⊙, which indicates a significantly stripped progenitor that was possibly in a binary system. We also followed up SN2019wxt with long-term Chandra and Jansky Very Large Array observations spanning ∼260 days. We detected no definitive counterparts at the location of SN2019wxt in these long-term X-ray and radio observational campaigns. We establish the X-ray upper limit at 9.93 × 10−17 erg cm−2 s−1 and detect an excess radio emission from the region of SN2019wxt. However, there is little evidence for SN1993J- or GW170817-like variability of the radio flux over the course of our observations. A substantial host-galaxy contribution to the measured radio flux is likely. The discovery and early-time peak capture of SN2019wxt in optical/NIR observations during EMGW follow-up observations highlight the need for dedicated early, multiband photometric observations to identify USSNe

Arrhythmic risk profile and outcomes of patients undergoing cardiac sympathetic denervation for recurrent monomorphic ventricular tachycardia after ablation

Background Cardiac sympathetic denervation (CSD) has been used as a bailout strategy for refractory ventricular tachycardia (VT). Risk of VT recurrence in patients with scar-related monomorphic VT referred for CSD and the extent to which CSD can modify this risk is unknown. We aimed to quantify arrhythmia recurrence risk and impact of CSD in this population. Methods and Results Adjusted competing risk time to event models were developed to adjust for risk of VT recurrence and sustained VT/implantable cardioverter-defibrillator shocks after VT ablation based on patient comorbidities at the time of VT ablation. Adjusted VT and implantable cardioverter-defibrillator shock recurrence rates were estimated for the subgroup who subsequently required CSD after ablation. The expected adjusted recurrence rates were then compared with the observed rates after CSD. Data from 381 patients with scar-mediated monomorphic VT who underwent VT ablation were analyzed, excluding patients with polymorphic VT. Sixty eight patients underwent CSD for recurrent VT. CSD reduced the expected adjusted VT recurrence rate by 36% (expected rate of 5.61 versus observed rate of 3.58 per 100 person-months, P=0.01) and the sustained VT/implantable cardioverter-defibrillator shock rates by 34% (expected rate of 4.34 versus observed 2.85 per 100 person-months, P=0.03). The median number of sustained VT/implantable cardioverter-defibrillator shocks in the year before versus the year after CSD was reduced by 90% (10 versus 1, P<0.0001). Conclusions Patients referred for CSD for refractory scar-mediated monomorphic VT are at a higher risk of VT recurrence after ablation as compared with those not requiring CSD, mostly because of their cardiac comorbidities. CSD significantly reduced both the expected risk of recurrences and VT burden

Initial Independent Outcomes from Focal Impulse and Rotor Modulation Ablation for Atrial Fibrillation: Multicenter FIRM Registry

Introduction The success of pulmonary vein isolation (PVI) for atrial fibrillation (AF) may be improved if stable AF sources identified by Focal Impulse and Rotor Mapping (FIRM) are also eliminated. The long-term results of this approach are unclear outside the centers where FIRM was developed; thus, we assessed outcomes of FIRM-guided AF ablation in the first cases at 10 experienced centers. Methods We prospectively enrolled n = 78 consecutive patients (61 ± 10 years) undergoing FIRM guided ablation for persistent (n = 48), longstanding persistent (n = 7), or paroxysmal (n = 23) AF. AF recordings from both atria with a 64-pole basket catheter were analyzed using a novel mapping system (Rhythm View™; Topera Inc., CA, USA). Identified rotors/focal sources were ablated, followed by PVI. Results Each institution recruited a median of 6 patients, each of whom showed 2.3 ± 0.9 AF rotors/focal sources in diverse locations. 25.3% of all sources were right atrial (RA), and 50.0% of patients had ≥1 RA source. Ablation of all sources required a total of 16.6 ± 11.7 minutes, followed by PVI. On >1 year follow-up with a 3-month blanking period, 1 patient lost to follow-up (median time to 1st recurrence: 245 days, IQR 145–354), single-procedure freedom from AF was 87.5% (patients without prior ablation; 35/40) and 80.5% (all patients; 62/77) and similar for persistent and paroxysmal AF (P = 0.89). Conclusions Elimination of patient-specific AF rotors/focal sources produced freedom-from-AF of ≈80% at 1 year at centers new to FIRM. FIRM-guided ablation has a rapid learning curve, yielding similar results to original FIRM reports in each center’s first cases